Navigation Links
OctreoPharm Sciences GmbH Granted Global and Exclusive License for Oncology Diagnostic Product
Date:10/6/2011

BERLIN, October 6, 2011 /PRNewswire/ --

OctreoPharm Sciences GmbH, a Berlin-based specialist in nuclear medical pharmaceuticals (radiopharmaceuticals), announced today that it has received the worldwide exclusive license for the development and commercialization of SOMscan™, from Novartis Pharma AG.

The new Gallium-68-labeled radioactive contrast agent for positron emission tomography (PET) used by SOMscan has the potential to selectively detect and monitor neuroendocrine tumors. Following its potentialregistration, it could be, amongst other applications, used for this indication in conjunction with a new therapeutic drug.

SOMscan binds to four out of five specific receptor subtypes for the naturally-occurring hormone, somatostatin, on the cell surface of neuroendocrine tumors and uses high-resolution combined positron emission tomography and computed tomography (PET/CT) technique. This may allow detection of neuroendocrine tumors and metastases which previously escaped discovery in imaging diagnoses.  The only agent registered to date for the diagnosis of these tumors binds to only one of these receptor subtypes and uses the less sensitive gamma camera technique.

By leveraging high-resolution PET/CT imaging technique, the diagnosis of neuroendocrine tumors with SOMscan has the potential to be faster, more accurate, more reliable and more specific - with a marked reduction of radiation exposure for the patient. The expectation is that tumors and metastases down to a size of approximately four millimeters can be detected in accurate anatomical correlation with SOMscan. Since both the SOMscan diagnostic and therapeutic agent bind to the same tumor receptors, this makes individual monitoring and management of the course of the disease possible - another step towards personalized medicine… [http://www.octreopharmsciences.com/images/pdf/20111005_ops_pressrelease.pdf].

Contact:
Udo Blaseg
OctreoPharm Sciences GmbH
Campus Berlin-Buch
Robert-Rössle-Straße 10
13125 Berlin
Phone:  +49(0)30-9489-3360
eMail:  udo.blaseg@octreopharm.com



'/>"/>
SOURCE OctreoPharm
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Inovio Pharmaceuticals Leadership for Life Sciences Recognized in the Philadelphia Region
2. SV Life Sciences Appoints Veteran Diagnostics Professional Dr. Heiner Dreismann as Venture Partner
3. Particle Sciences Granted Patent on Self Sterilizing Medical Devices
4. Neurocrine Biosciences Receives Second Milestone Payment of $20 Million Under Abbott Collaboration Agreement
5. Coronado Biosciences Appoints Noah D. Beerman as Executive Vice President and Chief Operating Officer
6. ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreichs Ataxia
7. Regado Biosciences, Inc. to Present at the Sofinnova Japan Biopharma Partnering Conference in Tokyo, Japan
8. BD Biosciences Introduces New Device Designed to Increase Cell Growth and Cell Culture Productivity
9. Neurocrine Biosciences Announces Elagolix Scientific Presentations at the 67th Annual Meeting of the American Society for Reproductive Medicine
10. Valeant Pharmaceuticals Intends to Raise Offer for Afexa Life Sciences Inc. to $0.85 per Share
11. Sangamo BioSciences Announces Presentation at the Sixth Annual JMP Securities Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 2017 The global  pacemaker market  is expected to reach ... Research, Inc. The heightening prevalence of cardiac conditions coupled with the availability of ... In addition, technological enhancements in these devices are supporting the expansion of this ... ... Grand View Research Logo ...
(Date:1/19/2017)... The Global Therapy Partnering Terms and Agreements since 2010 ... agreements entered into by the world,s leading healthcare companies. ... by value - Deals listed by company A-Z, industry ... provides understanding and access to the partnering deals and ... The report provides an analysis of partnering deals. ...
(Date:1/19/2017)... Jan. 18, 2017 The drug delivery technology ... 2021 from USD 1,179.20 billion in 2016, at a ... prevalence of chronic diseases, increasing demand for biologics, technological ... the growth of this market. Whereas, self-administration & home ... offer significant growth opportunities for players operating in this ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... January 19, 2017 , ... Remote ... recently unveiled impressive transportable capabilities with their iMedHD2™ Portable Teleultrasound System. ... to RMT technology that delivers HD, dynamic, streaming ultrasound images and video to ...
(Date:1/19/2017)... ... January 19, 2017 , ... MB Business Capital, a division ... credit facility to Sunrise, Florida-based Management Health Systems, LLC, dba MedPro Healthcare Staffing ... recapitalization of MedPro led by Harren Equity Partners. Brightwood Capital Advisors provided ...
(Date:1/19/2017)... PETALUMA, CA (PRWEB) , ... January 19, 2017 ... ... new Tranquility acoustic and privacy panel system. , The Tranquility privacy panel ... to a collaborative office environment. Tranquility panels help reduce noise and provide the ...
(Date:1/19/2017)... ... January 19, 2017 , ... Tribble Insurance Agency, a family ... Virginia region, is inaugurating a charity event to honor Chad Phillip Dermyer, a local ... last year, Chad Phillip Dermyer and his fellow officers were conducting routine stops of ...
(Date:1/19/2017)... ... January 19, 2017 , ... For the ... Medicine Associates of Connecticut (RMACT) have earned “Top Doctor” awards. Dr. Mark Leondires, ... Williams have each been chosen by their peers for the 2017 list based ...
Breaking Medicine News(10 mins):